跳转至内容
Merck
CN
  • Intracranial pressure response after pharmacologic treatment of intracranial hypertension.

Intracranial pressure response after pharmacologic treatment of intracranial hypertension.

The journal of trauma and acute care surgery (2014-07-01)
Katharine Colton, Shiming Yang, Peter F Hu, Hegang H Chen, Brandon Bonds, Thomas M Scalea, Deborah M Stein
摘要

The accepted treatment of increased intracranial pressure (ICP) in patients experiencing severe traumatic brain injury is multimodal and algorithmic, obscuring individual effects of treatment. Using continuous vital signs monitoring, we sought to measure treatment effect and ascertain the accuracy of manual data recording. Patients older than 17 years, admitted and requiring ICP monitoring between 2008 and 2010 at a high-volume urban trauma center, were retrospectively evaluated. Timing and dose of ICP-directed therapy were recorded from paper and electronic medical records. ICP data were collected automatically at 6-second intervals and from manual charts. A statistical mixed model was applied to all data to account for multiple sampling. A total of 117 patients met inclusion criteria; 450 treatments were administered when nursing records indicate an ICP greater than 20 mm Hg, while 968 treatments were given when ICP was greater than 20 mm Hg by automated data. Pharmacologic treatments identified include hypertonic saline (HTS), mannitol, barbiturates, and dose escalations of propofol or fentanyl infusions. Treatment with HTS resulted in the largest ICP decrease of the treatments examined, with a 1-hour ICP reduction of 8.8/9.9 mm Hg (for a small/large dose) according to manual data and a reduction of 3.0/2.4 mm Hg according to automated data. Propofol and fentanyl escalations resulted in smaller but significant ICP reductions. Mannitol (n = 8) resulted in statistically insignificant trends down in the first hour but rebounded by the second hour after administration. The average ICP in the hour before medication administration was higher for barbiturates (27 mm Hg) and mannitol (32 mm Hg) than for the other interventions (18-19 mm Hg). ICP fell after administration of HTS, mannitol, or barbiturates and showed continued improvement after 2 hours. ICP fell initially after treatment with short-acting propofol and fentanyl but trended back up after 2 hours. Manually recorded data consistently overestimated treatment effectiveness. Automated data collection gives a more accurate assessment of patient status and responsiveness to treatment. Therapeutic study, level IV.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
D -甘露醇, ≥98% (GC)
Supelco
甘露醇, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
D -甘露醇, ACS reagent
Sigma-Aldrich
D -甘露醇, ≥98% (GC), suitable for plant cell culture
USP
甘露醇, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
D -甘露醇, BioUltra, ≥99.0% (sum of enantiomers, HPLC)
Sigma-Aldrich
D -甘露醇, meets EP, FCC, USP testing specifications
Sigma-Aldrich
D -甘露醇, BioXtra, ≥98% (HPLC)
甘露醇, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
普鲁泊福, 97%
Millipore
D -甘露醇, ACS reagent, suitable for microbiology, ≥99.0%
Supelco
丙泊酚标准液 CRM 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
D -甘露醇, tested according to Ph. Eur.
普鲁泊福, European Pharmacopoeia (EP) Reference Standard
Supelco
D -甘露醇, ≥99.9999% (metals basis), for boron determination